Effector Therapeutics Inc (EFTR) — Strategic Asset Allocation Index
Effector Therapeutics Inc (EFTR) has a Strategic Asset Allocation Index of 11.6% as of June 2023. Strategic assets (PP&E of $299.00K plus long-term investments of $-) total $299.00K, measured against net assets of $2.58 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check EFTR financial resilience to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Effector Therapeutics Inc Strategic Asset Allocation Index (2021–2022)
This chart shows how Effector Therapeutics Inc's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 11.6%, representing strategic assets of $299.00K against net assets of $2.58 Million USD. See EFTR free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Effector Therapeutics Inc (2021–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Effector Therapeutics Inc from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Effector Therapeutics Inc market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 9.0% | $352.00K | $352.00K | $- | $3.90 Million | ▲ +8.5 pp |
| 2021 | 0.5% | $91.00K | $91.00K | $- | $17.28 Million | — |